Arsenic-induced NFKB transactivation through Erks-and JNKs-dependent pathways in mouse epidermal JB6 cells

  • Chuanshu Huang
  • Jingxia Li
  • Min Ding
  • Liying Wang
  • Xianglin Shi
  • Vincent Castranova
  • Val Vallyathan
  • Ju Gong
  • Max Costa
Part of the Developments in Molecular and Cellular Biochemistry book series (DMCB, volume 34)


Tumor promoting effects of arsenic are believed to be associated with its transactivation activity on transcription factors, such as AP-1 and NFKB. However, the results from different groups studying the effects of arsenic on NFKB activation are contradictory in different cell models. Since arsenic is a strong skin carcinogen, we have investigated the activation of NFKB by arsenic in a mouse skin epidermal cell line, JB6 cells. Exposure of cells to arsenite or arsenate led to NFKB transactivation in mouse epidermal JB6 NFKB-luciferase reporter stable transfectants, C141 NFKB mass,. This induction of NFKB activity by arsenic was dose-and time-dependent. The transactivation of NFKB by arsenic appeared to be through activation of Erks and JNKs pathways because increased NFKB activity by arsenic could be dramatically inhibited by either pre-treatment of cells with PD98059 or overexpression of dominant negative JNK,. That Erks activation is required for arsenic-induced NFKB transactivation was further supported by the findings that arsenic-induced NFKB transactivation was impaired in JB6 30.7b cells, which were deficient in Erks. (Mol Cell Biochem 222: 29-34, 2001)

Key words

arsenic NFKB MAP kinase 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Knowles FC, Benson AA: The enzyme inhibitory form of inorganic arsenic. Z Gesamte Hyg 30: 625–626, 1984PubMedGoogle Scholar
  2. 2.
    Bettley FR, O’Shea JA: The absorption of arsenic and its relation to carcinoma. Br J Dermatol 92: 563–568, 1975PubMedCrossRefGoogle Scholar
  3. 3.
    Landolph JR: Molecular mechanisms of transformation of C31H ‘DTI/ 2 Cl 8 mouse embryo cells and diploid human fibroblasts by carcinogenic metal compounds. Environ Health Perspect 102(suppl 3): 119–125, 1994Google Scholar
  4. 4.
    Evans S: Arsenic and cancer. Br J Dermatol 97(suppl 15): I3, 1977CrossRefGoogle Scholar
  5. 5.
    Gayer RA: Toxic effects of metals. In: C.D. Klaassen, M.O. Amdur, J. Douil (eds). Toxicology. The Basic Science of Poisons. Macmillan Publishing Company, New York, 1986, pp 582–635Google Scholar
  6. 6.
    Chen C-J,Wang C-J: Ecological correlation between arsenic Level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res 50: 5470–5474, 1990PubMedGoogle Scholar
  7. 7.
    Chan PC, Huff J: Arsenic carcinogenesis in animals and in humans: Mechanistic, experimental, and epidemiological evidence. Environ Carcinogen Ecotoxicol Rev C l5: 83–122, 1997CrossRefGoogle Scholar
  8. 8.
    National Institute for Occupational Safety and Health: National Occupational Exposure Survey (1980–1983). Department of Health and Human Services, Cincinnati, OH, 1984Google Scholar
  9. 9.
    Lansdown ABG: Physiological and toxicological changes in the skin resulting from the action and interaction of metal ions. Crit Rev Toxicol 25: 397–462, 1995PubMedCrossRefGoogle Scholar
  10. 10.
    Luchtrath H: The consequences of chronic arsenic poisoning among Moselle wine growers. Pathoanatomical investigations of post-mortem examinations performed between 1960 and 1977. J Cancer Res Clin Oncol 105: 173–182, 1983CrossRefGoogle Scholar
  11. 11.
    Philipp R: Arsenic exposure: Health effects and the risk of cancer. Rev Environ Health 5: 27–57, 1985PubMedGoogle Scholar
  12. 12.
    Snow ET: Metal carcinogenesis: mechanistic implications. Pharmac Thcr 53: 31–65, 1992Google Scholar
  13. 13.
    Huang C, Ma W-Y, Li J, Goranson A, Dong Z: Requirement of Erks, but not JNKs, for arsenite-induced cell transformation. J Biol Chem 274: 14595–14601, 1999PubMedCrossRefGoogle Scholar
  14. 14.
    Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M: The tumor promoter arsenite stimulates AP-1 activity by inhibiting a INK phosphatase. EMBO J 15: 6269–6279, 1996PubMedGoogle Scholar
  15. 15.
    Ludwig S, Hoffmeyer A, Goebeler M, Kilian K, Häfner H, Neufeld B, Han J, Rapp UR: The stress inducer arsenite activates mitogen-activated protein kinases extraceilular signal-regulated kinases 1 and 2 via a MAPK kinase 6/p38-dependent pathway. J Biol Chem 273: 1917–1922, 1998PubMedCrossRefGoogle Scholar
  16. I6.
    Huang C, Ma WY, Li J. Dong Z: Arsenic induces apoptosis through a c-Jun NI-12-terminal kinase-dependent, p53-independent pathway. Cancer Res 59: 3053–3058, 1999PubMedGoogle Scholar
  17. 17.
    Huang C, Ma W-Y, Bowden GT, Dong Z: Ultraviolet B-induced activated protein-1 activation does not require epidermal growth factor receptor but is blocked by a dominant negative PKCXIi. J Biol Chem 49: 31262–31268, 1996Google Scholar
  18. 18.
    Huang C, Chen N, Ma W-Y, Dong Z: Vanadium induces AP-1 and NFKB-dependent transcription activity. int.’ Oncol 13: 711–715.Google Scholar
  19. 19.
    Huang C, Ma W-Y, Young MR, Colburn N, Dong Z: Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc Nat] Acad Sci USA 95: 156–161, 1998CrossRefGoogle Scholar
  20. 20.
    Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH: Blocking tumor promoter induced AP-1 activity inhibits induced transformation in JB6 cells. Proc Nat1 Acad Sci USA 91: 609–613, 1994CrossRefGoogle Scholar
  21. 21.
    Bernstein LR, Colbum NH: AP-Iljun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science 244: 566–569, 1989PubMedCrossRefGoogle Scholar
  22. 22.
    Watts RG, Huang C, Young MR, Li JJ, Dong Z, Pcnnie WD, Colburn NH: Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene 17: 3493–3498, 1998PubMedCrossRefGoogle Scholar
  23. 23.
    Huang C, Li J, Ma W-Y, Dong, Z: JNKs activation is required for JB6 cell transformation induced by TNF-a but not by TPA. J Biol Chem 274: 29672–29676, 1999PubMedCrossRefGoogle Scholar
  24. 24.
    Huang, C, Li J, Ma W-Y, Chen N-Y, Dong Z: Activation ofAP-1 by arsenate and arsenate in both cell and AP-1 luciferase-transgenic mice. FASEB J: 2000 (submitted)Google Scholar
  25. 25.
    Chen N, Ma W-Y, Huang C, Ding M, Dong Z: Activation of PKC is required for arsenate-induced signal transduction, J Environ Pathol Toxicol Oncol 19: 297–305, 2000PubMedGoogle Scholar
  26. 26.
    Baldwin A: The NF-KB and 1KB proteins: New discoveries and insights. Annu Rev Immunol 14: 649--683, 1996PubMedCrossRefGoogle Scholar
  27. 27.
    Ghosh S, May MJ, Kopp EB: NF-KB and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225–260, 1998PubMedCrossRefGoogle Scholar
  28. 28.
    Li JI, Westergaard C, Ghosh P, Colbum NH: Inhibitors of both nuclear factor-KB and activator protein-1 activation block the neoplastic transformation response_ Cancer Res 57: 3569–3576, 1997PubMedGoogle Scholar
  29. 29.
    Gilmore TD, Koedood M, Piffat KA, White DW: ReIINF-iBIKB proteins and cancer. Oncogene 13: 1367–1378, 1996PubMedGoogle Scholar
  30. 30.
    Baeuerlc PA, Baltimore D: NF-KB: Ten years after, Cell 87: 13–20, 1996CrossRefGoogle Scholar
  31. 31.
    Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S: Re11NF-KBIIKB family: Intimate tales of association and dissocia-tion. Genes Dey 9: 2723–2735, 1995CrossRefGoogle Scholar
  32. 32.
    Galang CK, Garcia-Ramirez J, Solski PA, Westwick IK, Der CJ, Neznanov NN, Oshima RG, Hauser CA: Oncogenic Neu/Erb/3–2 increases Ets, AP-1, and NF-KB-dependent gene expression, and inhibiting Etsactivation blocks Neu-mediated cellular transformation. J Biol Chem 271: 7992–7998, 1996PubMedCrossRefGoogle Scholar
  33. 33.
    Finco TS, Baldwin AS Jr: Kappa B site-dependent induction of gene expression by diverse inducers of nuclear factor KB requires Raf--1. J Biol Chem 268: 17676–17679, 1993PubMedGoogle Scholar
  34. 34.
    Bruder JT, Heidecker G, Rapp UR: Serum-, TPA-, and Ras-induced expression from Ap-11Ets-driven promoters requires Raf-1 kinase. Genes Dev 6: 545–556, 1992PubMedCrossRefGoogle Scholar
  35. 35.
    Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin AS Jr: Oncogenic Ha-Ras-induced signaling activates NF-KB transcriptional activity, which is required for cellular transformation. J Biol Chem 272: 24113–24116,1997PubMedCrossRefGoogle Scholar
  36. 36.
    Simeonova PP, Luster MI: Mechanisms of arsenic carcinogenicity: genetic or epigenetic mechanisms?J Environ Pathol Toxicol Oncol 19: 281–286, 2000Google Scholar
  37. 37.
    Simeonova PP, Wang S, Toriuma W, Kommineni V, Matheson J, Unimye N, Kayama F, Harki D, Ding M, Vallyathan V, Luster MI: Arsenic mediates cell proliferation and gene expression in the bladder epithelium: Association with activating protein-1 transactivation. Cancer Res 60: 3445–3453, 2000PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Chuanshu Huang
    • 1
  • Jingxia Li
    • 1
  • Min Ding
    • 2
  • Liying Wang
    • 2
  • Xianglin Shi
    • 2
  • Vincent Castranova
    • 2
  • Val Vallyathan
    • 2
  • Ju Gong
    • 3
  • Max Costa
    • 1
  1. 1.Nelson Institute of Environmental MedicineNew York University School of MedicineNY
  2. 2.Health Effects Laboratory DivisionNational Institute for Occupational Safety and Health, Morgantown, WVUSA
  3. 3.The Institute of NeuroscienceThe Fourth Military Medical UniversityXi’anP.R. China

Personalised recommendations